SCYNEXIS, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
SCYNEXIS, Inc. (SCYX) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$427.00 thousand for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2023-11-13
- SCYNEXIS, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2023-09-30 was $2.07M.
- SCYNEXIS, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2023-06-30 was $4.21M, a 12.49% increase year-over-year.
- SCYNEXIS, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2023-03-31 was -$6.70M, a 1849.61% decline year-over-year.
- SCYNEXIS, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2022-12-31 was -$140.00K.
- SCYNEXIS, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $2.29M, a 53.75% decline from fiscal 2021.
- SCYNEXIS, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2021 was $4.94M, a 1525.33% increase from fiscal 2020.
- SCYNEXIS, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2020 was $304.00K.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2023-09-30 | $2.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $6.27M derived: sum of 2 quarters · filed 2023-11-13 | -$427.00K 10-Q · filed 2023-11-13 | -$567.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | $4.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$2.49M 10-Q · filed 2023-08-14 | -$2.63M derived: sum of 3 quarters · filed 2023-08-14 | -$4.33M derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-03-31 | -$6.70M 10-Q · filed 2023-05-10 | -$6.84M derived: sum of 2 quarters · filed 2023-05-10 | -$8.54M derived: sum of 3 quarters · filed 2023-11-13 | -$4.80M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-12-31 | -$140.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$1.84M derived: sum of 2 quarters · filed 2023-11-13 | $1.90M derived: sum of 3 quarters · filed 2023-11-13 | $2.29M 10-K · filed 2023-03-31 |
| 2022-09-30 | -$1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $2.04M derived: sum of 2 quarters · filed 2023-11-13 | $2.42M 10-Q · filed 2023-11-13 | $2.38M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $3.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $4.12M 10-Q · filed 2023-08-14 | $4.07M derived: sum of 3 quarters · filed 2023-08-14 | $7.85M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $383.00K 10-Q · filed 2023-05-10 | $334.00K derived: sum of 2 quarters · filed 2023-05-10 | $4.11M derived: sum of 3 quarters · filed 2023-05-10 | $5.39M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$49.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $3.73M derived: sum of 2 quarters · filed 2023-03-31 | $5.01M derived: sum of 3 quarters · filed 2023-03-31 | $4.94M 10-K · filed 2023-03-31 |
| 2021-09-30 | $3.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $5.06M derived: sum of 2 quarters · filed 2022-11-09 | $4.99M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $1.21M 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | -$68.00K 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $304.00K 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |